LearnGlossaryMarketStocksSuperinvestorsSign in

PEPG

PepGen Inc.

Healthcare · $179M market cap

Verdict

We can't put a fair value on PEPG right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-12.5% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-64.5%✗

Follow PEPG

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds PEPG. Who we track

Viking Global Investors

Viking Global Investors · as of Q2 2026

$6.3M

3,482,434 shares

About PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works